Revolution Medicines, Inc.
RVMD
$41.88
$1.463.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 9.39% | 23.95% | |||
| Gross Profit | -9.39% | -23.95% | |||
| SG&A Expenses | 24.09% | 17.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.30% | 23.10% | |||
| Operating Income | -11.30% | -23.10% | |||
| Income Before Tax | -9.26% | -24.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.69% | -24.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.69% | -24.49% | |||
| EBIT | -11.30% | -23.10% | |||
| EBITDA | -11.41% | -23.27% | |||
| EPS Basic | -1.29% | -19.55% | |||
| Normalized Basic EPS | -0.90% | -20.00% | |||
| EPS Diluted | -1.29% | -19.55% | |||
| Normalized Diluted EPS | -0.90% | -20.00% | |||
| Average Basic Shares Outstanding | 8.28% | 4.14% | |||
| Average Diluted Shares Outstanding | 8.28% | 4.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||